Ritlecitinib、LITFULO、利特昔替尼

Ritlecitinib

Another Name
Ritlecitinib、LITFULO、利特昔替尼
Indications
Suitable for treating severe alopecia areata in adults and adolescents aged 12 and above.
Reg No
10 L 1035/23
Inspection No
2581-23
dosage form:capsule
Specs:50mg
Indate:24 months
Date：2024-9-1 Views：1199
Drug Info

COMPOSITION:

Each LuciRit capsule contains Ritlecitinib tosylate 80.13 mg equivalent to Ritlecitinib………………..50 mg

INDICATION:

LuciRit is a kinase inhibitor indicated for the treatment of severe alopecia areata in adults and adolescents 12 years and older.

DOSAGE AND USE:

The recommended dosage of LuciRit is 50 mg orally once daily with or without food. If treatment interruption is indicated, a temporary treatment interruption for less than 6 weeks is not expected to result in significant loss of regrown scalp hair.

Capsule should be swallowed whole & not chewed or crushed

STORAGE:

in a dry place and store at 20°C to 25°C.

MANUFACTURED AND MARKETED BY:

LUCIUS PHARMACEUTICALS(LAO) CO., LTD

No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos

WARNING:

Keep medicine out of reach of Children. Do not administered LuciRit in Pregnancy and Lactation patient treatment.

Original article, if reprinted, please indicate the link to this article: https://lucius-pharmaceuticals.com/drug/ritlecitinib/

Related News